An observational study in Drug Resistant Epilepsy, Autism Spectrum Disorder and Chronic Migraine, sponsored by Danone Nutricia SpA Società Benefit. Recruiting at 3 sites in Italy. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Danone Nutricia SpA Società Benefit (part of Danone) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Drug Resistant Epilepsy with a site in Italy — 7 open to participants now, 10 under way, 1 of them phase 3. Drug Resistant Epilepsy · Italy.
Among the 21 studies in Drug Resistant Epilepsy with a site in Italy, this one is one of 4 that started in 2022, is one of 8 observational ones, and was the 16th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →7 of the 21 studies in Drug Resistant Epilepsy with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 3–50
IRCCS San Raffaele · Sites in Italy
Ages 18–60
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 18+
Neuromed IRCCS · Sites in Italy
University of Pavia · Sites in Italy
Ages 12–35 · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 86 across 45 observational studies indexed under Drug Resistant Epilepsy.
Median enrollment 232 across the 13 interventional studies, 115 across the 8 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Danone Nutricia SpA Società Benefit, one of the names counted as Danone. Under that name alone:
This is the only study on the registry with Danone Nutricia SpA Società Benefit as lead sponsor.
Danone has 3 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
4 of the studies in Drug Resistant Epilepsy with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT07010445Niguarda HospitalMiCrobiota-gut-brain Axis in Resistant Epilepsy | 2027-02-28 |
| NCT06210022IRCCS San RaffaeleCognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy | 2027-03-01 |
| NCT06724029Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeurosurgical Outcome Network | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Drug Resistant Epilepsy with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
The main question[s] it aims to answer are:
Scientific and clinical interest in KD is growing with a progressive increase in its therapeutic indications, ie recent studies show beneficial effects of KD in other diseases like migraine, autism spectrum disorder and brain tumors.
However, so far, the majority of results on KD effects have been collected in patients with drug-resistant epilepsy proving its effectiveness on clinical outcome (e.g. reducing epileptic seizures), frequently leaving out the nutritional assessment and the impact on quality of life. Nonetheless, these factors are indeed essential to ensure safety and efficacy of KD treatment, especially when dealing with children and in perspective of the progressive expansion of the target population that can benefit from this nutritional therapy.
The present multicenter study aims to analyse these poorly explored areas, by evaluating, in a cohort of pediatrics patient with indication to KD therapy, not only the KD effectiveness on the course of the underlying disease, but also the impact on nutritional parameters (e.g. growth, lipid profile, vitamin intake, bone mineral density, ..) and on quality of life.
Pediatri patients (0-18 years) affected by any disease which require a ketogenic diet (KD), i.e. metabolic or genetic disorder or neurological (congenital and acquired) diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric patients with any disease which require a ketogenic diet (KD), i.e. metabolic or genetic disorder or neurological (congenital and acquired) diseases
Other: ketogenic diet (as per clinical practice)
Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
Nutritional adequacy
evaluate the nutritional adequacy of the diet after 6 months of treatment with ketogenic diet (KD) in terms of adequate growth defined by weight-for-age Z Score (WAZ) and length-for-age Z score (LAZ).
Time frame: 6 months
Nutritional adequacy
Evaluate the nutritional adequacy of the diet after 6 and 12 months of treatment with ketogenic diet (KD) in terms of correct growth defined by: Weight-for-age Z-score (WAZ), length/height-for-age z-score (LAZ), BMI z-score Blood levels of selected parametres (eg cholesterol, HDL, LDL) within normal ranges Body composition (optional)
Time frame: 6 months,(12 months optional)
% of responders to KD
Evaluate the effectiveness of the ketogenic diet (KD) on the clinical outcomes (% of responders): * Epilepsy: at least 50% seizure reduction after 6 months of KD treatment (vs 6 months before trial start( (daily diary records) * ASD: reduction of at least 2-8 in CARS score after 6 months of KD treatment * Chronic migraine: at least 50% episodes reduction after 6 months of KD treatment (vs 6 months before trial start( (daily diary records); reduction \>=50% of PedMiDas score after 6 months of KD treatment (vs baseline) Brain tumors: % survival; % of subjects with progression free survival
Time frame: 6 months,(12 months optional)
Health related quality of life improvement through parent questionnaire
Evaluate the effectiveness of the ketogenic diet (KD) on the patient's quality of life using a non-validated questionnaire administered to parents with qualitative open and closed questions. Improvement will be considered as an improvement in the score of disease burden related questions baseline vs end of observation
Time frame: 6 months,(12 months optional)
Plan to share: No
Started Mar 2022 (actual). Primary completion is estimated for Dec 2025, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.